Castle Biosciences acquires Cernostics for up to $30M upfront plus $50M earnout

CASTLE BIOSCIENCES INC

Up-front consideration $30M (cash or cash/stock mix); earnouts up to $50M based on 2022 commercial milestones.
Cernostics 9M2021 revenue $469K, net loss $2.8M; 2020 revenue $141K, net loss $2.6M.
Cernostics' TissueCypher Barrett's Esophagus Assay added to Castle's diagnostics portfolio.
Transaction closed December 2021; amendment files required financial statements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.